EAPH‘s breakout into double digits signals the start of a major bullish run and is now setting up for a solid entry point to load up on a minor dip. Low volume pull backs gives strength to a bullish run, providing solid supports to spring from.
BRYN continue to hold solid at support levels and an excellent entry point as we eagerly wait for the report by Trueclaim (TRM.V) towards the 43-101 next month - this can kickstart this in high gear – take the opportunity now.
Our recent monster winner DEGH, had several low volume pullbacks (Blue circles) just before its trigger breakout point to our $0.75 target - a 50,000% gain from our original alert.
Investors who sold way too early and at prices way too low, missed out on as much as 10,000% gains. Not to mention investors who did not act at all missing out on a potential 50,000% gainer. Plus DEGH continues to hold on to its massive gains.
EAPH is not even close to its maximum potential gain – smart buyers see this and are accumulating a solid position at these low levels.
EAPH 29.25% gain yesterday is an initial indication of the kinetic energy stored making this a solid break out play that can see double/triple action.
Winston & Strawn LLP - North American distribution is closer than ever!
Winston & Strawn LLP, a large multinational Law Firm is well versed with all types of patent filings including pharmaceutical and OTC transdermal type of products such as the “Viorra” brand product – expect them to get the job done quickly and push into North American Distribution!
EAPH last traded at $0.09 and bounce off the 50 DMA support line, making this a solid level to grab some cheap shares for the next move higher – DEGH quickly jumped several times when this same level was breached!
With EAPH releasing monster PRs after another and a research report to be issued by http://www.directglobalmedia.com this weekend - it’s anyone’s guess where this is headed to
$2 BILLION Dollar Market for ViorraTM
Easton Pharmaceuticals is targeting the estimated $2 billion market for FSAD. Easton is also developing a pipeline of transdermal products using its proprietary technology
in Viorra for the estimated $2 billion male sexual dysfunction market, plus a variety of topical applications, including treatments for women and men seeking to diminish scars, adhesions, cellulite, varicose veins and stretch marks.
You can also keep up-to-date with Easton Pharmaceuticals product ViorraTM at http://emergingwomenshealthsolutions.com/index.html
Easton Pharmaceuticals Announces Retaining Winston & Strawn For Patent Application Submission
Easton Pharmaceuticals Inc, a specialty pharmaceutical company that designs, develops, and markets topically-delivered healthcare products, announces it has retained Winston & Strawn LLP as its patent attorneys for a patent application submission directed to its Viorra brand product and proprietary transdermal technology.
A retainer was advanced after a consultation with the firm to act as it’s patent attorneys on an anticipated patent application submission. Winston & Strawn is a large multinational law firm. The firm’s patent attorneys , including those based in Washington, D.C., are well versed with all types of patent filings including pharmaceutical and OTC transdermal type of products such as the “Viorra” brand product.
The ‘Viorra’ brand product is a cosmeceutical retail product that the company anticipates to launch in North America, South America, Mexico and East Asian markets. Viorra™ is expected to be Easton Pharmaceuticals first product to market which is a non-invasive topical treatment intended to assist women suffering from a range of Female Sexual Arousal Disorders (FSAD), including physical conditions that cause a lack of vaginal elasticity, lubricity and sensation.
Viorra As An Alternative To Ineffective Hormonal Therapies
“Millions of women have discovered that traditional hormonal therapies offered by the pharmaceutical industry for the past 50 years are simply not effective in allowing women to enjoy normal sexual intimate pleasure and sensation,” stated John Easton C.E.O and Chairman of the Board of Easton Pharmaceuticals. “Most women do not want to use a ‘drug’ for these conditions. Viorra is an over-the-counter topical gel that is safe, effective, and with daily use restores a woman’s vaginal lubricity, and assists in improved sensation.
$5.5 Billion Market
A publicly-traded company listed on the NASDAQ and the OTCPK, Easton Pharmaceuticals is targeting the estimated $2 billion market for FSAD. Easton is also developing a pipeline of transdermal products using the VD™ technology in Viorra for a variety of applications including topical treatments for women and men seeking to diminish scars, adhesions, cellulite, varicose veins, and stretch marks. The Company believes these additional applications target an estimated $3.5 billion market for treatments to diminish the appearance of damaged and aging skin which Easton’s subsequent products will address. Easton Pharmaceuticals will shortly announce its management team of highly credentialed physicians, medical researchers, and pharmaceutical industry professionals, and will focus on rapid revenue-growth through an aggressive mix of traditional distribution channel-supported retail sales and emerging Internet-based marketing and sales opportunities.
ABOUT EAPH – EASTON PHARMACEUTICALS
Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops and markets a range of premium, topically delivered therapeutic health care products. The company’s proprietary gel formulation is an innovative and unique transdermal delivery system.
The system is the technology that allows for the rapid development of non-invasive, naturally derived topical solutions that have the ability to revitalize and stimulate the healing of a variety of skin and tissue conditions. The transdermal delivery system allows for the targeted delivery of active ingredients, vitamins and herbs through the skin to the underlying tissue.
The company has utilized its transdermal delivery system to develop a safe and effective female sexual enhancement product. The company’s goal is to develop a portfolio of topical pharmaceutical and cosmeceutical products targeting various skin and tissue conditions including: scars and stretch marks, cellulite and varicose veins.
Follow us on twitter at http://www.twitter.com/ourhotstockpick and become the first to see what our next HOT Stock Pick will be.
We continue watching BRYN very closely holding on to its 300% gains since our initial alert – trading patterns indicates that accumulation is building off solid support levels.
BRYN is working closely with Trueclaim (TRM.V) on their Nova Scotia property and the initial report is expected early next month.
By the way BRYN is trading, we anticipate some pleasant surprises. Don’t be surprised if shorts also have an ear to the ground trying to find out exactly what will be in that report.
With Trueclaim (TRM.V) quite active with their press releases we expect BRYN to come out with their own monster news on work performed by Trueclaim shortly. We are looking for that bonanza news to take us much closer to that 43-101 and tapping into a credit facility of up to $100 million in funding.
About Bryn Resources Inc.
Bryn Resources is a precious metals exploration company currently concentrating its efforts in Eastern Canada region holding 100% interest in Renfrew Nova Scotia that comprises of 62 Claims covering 2,480 acres, and 100% interest in Wine Harbour, Nova Scotia. These claims have historically demonstrated their mineralization and in the period between 1862 and 1939 yielded 42,726 ounces of gold from 83,000 tons of ore, for an average content of 0.52 ounces per ton. Bryn Resources Inc. continues to seek partnerships in proven mineralization which are close to the production phase